JP2021503914A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021503914A5 JP2021503914A5 JP2020528888A JP2020528888A JP2021503914A5 JP 2021503914 A5 JP2021503914 A5 JP 2021503914A5 JP 2020528888 A JP2020528888 A JP 2020528888A JP 2020528888 A JP2020528888 A JP 2020528888A JP 2021503914 A5 JP2021503914 A5 JP 2021503914A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- raav
- amino acid
- nucleotide sequence
- retinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 claims description 57
- 125000003729 nucleotide group Chemical group 0.000 claims description 57
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 35
- 108090000565 Capsid Proteins Proteins 0.000 claims description 23
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 23
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 10
- 230000002207 retinal effect Effects 0.000 claims description 10
- 238000006467 substitution reaction Methods 0.000 claims description 10
- 210000002845 virion Anatomy 0.000 claims description 10
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 claims description 9
- 208000007135 Retinal Neovascularization Diseases 0.000 claims description 9
- 101150030763 Vegfa gene Proteins 0.000 claims description 9
- 241000702421 Dependoparvovirus Species 0.000 claims description 8
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 8
- 238000003780 insertion Methods 0.000 claims description 8
- 230000037431 insertion Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 208000030533 eye disease Diseases 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 6
- 208000017442 Retinal disease Diseases 0.000 claims description 6
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 6
- 208000002780 macular degeneration Diseases 0.000 claims description 6
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 5
- 208000001344 Macular Edema Diseases 0.000 claims description 5
- 206010025415 Macular oedema Diseases 0.000 claims description 5
- 230000007850 degeneration Effects 0.000 claims description 5
- 201000011190 diabetic macular edema Diseases 0.000 claims description 5
- 230000000938 luteal effect Effects 0.000 claims description 5
- 201000010230 macular retinal edema Diseases 0.000 claims description 5
- 210000000234 capsid Anatomy 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 102220062241 rs786201968 Human genes 0.000 claims description 4
- 206010029113 Neovascularisation Diseases 0.000 claims description 3
- 206010038923 Retinopathy Diseases 0.000 claims description 3
- 229960002833 aflibercept Drugs 0.000 claims description 3
- 108010081667 aflibercept Proteins 0.000 claims description 3
- 201000005667 central retinal vein occlusion Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000002028 premature Effects 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 201000007737 Retinal degeneration Diseases 0.000 claims description 2
- 208000034698 Vitreous haemorrhage Diseases 0.000 claims description 2
- 210000003644 lens cell Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 208000001491 myopia Diseases 0.000 claims description 2
- 230000004379 myopia Effects 0.000 claims description 2
- 201000003142 neovascular glaucoma Diseases 0.000 claims description 2
- 210000001328 optic nerve Anatomy 0.000 claims description 2
- 229960003876 ranibizumab Drugs 0.000 claims description 2
- 239000002525 vasculotropin inhibitor Substances 0.000 claims description 2
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 claims 4
- 230000002452 interceptive effect Effects 0.000 claims 4
- 108090000102 pigment epithelium-derived factor Proteins 0.000 claims 4
- 210000001525 retina Anatomy 0.000 claims 3
- 102000009840 Angiopoietins Human genes 0.000 claims 2
- 108010009906 Angiopoietins Proteins 0.000 claims 2
- 102400000068 Angiostatin Human genes 0.000 claims 2
- 108010079709 Angiostatins Proteins 0.000 claims 2
- 102400001047 Endostatin Human genes 0.000 claims 2
- 108010079505 Endostatins Proteins 0.000 claims 2
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims 2
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 2
- 102100035194 Placenta growth factor Human genes 0.000 claims 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 2
- 101150091393 Vegfb gene Proteins 0.000 claims 2
- 101150036482 Vegfc gene Proteins 0.000 claims 2
- 101150111878 Vegfd gene Proteins 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 208000024080 Myopic macular degeneration Diseases 0.000 claims 1
- 208000014139 Retinal vascular disease Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 210000003161 choroid Anatomy 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000001957 retinal vein Anatomy 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 201000007917 background diabetic retinopathy Diseases 0.000 description 1
- 229950000025 brolucizumab Drugs 0.000 description 1
- 208000027129 choroid disease Diseases 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022101767A JP2022121534A (ja) | 2017-11-27 | 2022-06-24 | アデノ随伴ウイルス変異キャプシドおよび血管新生の阻害のための使用 |
| JP2023205214A JP2024015194A (ja) | 2017-11-27 | 2023-12-05 | アデノ随伴ウイルス変異キャプシドおよび血管新生の阻害のための使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762590976P | 2017-11-27 | 2017-11-27 | |
| US62/590,976 | 2017-11-27 | ||
| US201862664726P | 2018-04-30 | 2018-04-30 | |
| US62/664,726 | 2018-04-30 | ||
| PCT/US2018/062478 WO2019104279A1 (en) | 2017-11-27 | 2018-11-26 | Adeno-associated virus variant capsids and use for inhibiting angiogenesis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022101767A Division JP2022121534A (ja) | 2017-11-27 | 2022-06-24 | アデノ随伴ウイルス変異キャプシドおよび血管新生の阻害のための使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021503914A JP2021503914A (ja) | 2021-02-15 |
| JP2021503914A5 true JP2021503914A5 (enExample) | 2021-07-26 |
| JP7184894B2 JP7184894B2 (ja) | 2022-12-06 |
Family
ID=66631726
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020528888A Active JP7184894B2 (ja) | 2017-11-27 | 2018-11-26 | アデノ随伴ウイルス変異キャプシドおよび血管新生の阻害のための使用 |
| JP2022101767A Pending JP2022121534A (ja) | 2017-11-27 | 2022-06-24 | アデノ随伴ウイルス変異キャプシドおよび血管新生の阻害のための使用 |
| JP2023205214A Pending JP2024015194A (ja) | 2017-11-27 | 2023-12-05 | アデノ随伴ウイルス変異キャプシドおよび血管新生の阻害のための使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022101767A Pending JP2022121534A (ja) | 2017-11-27 | 2022-06-24 | アデノ随伴ウイルス変異キャプシドおよび血管新生の阻害のための使用 |
| JP2023205214A Pending JP2024015194A (ja) | 2017-11-27 | 2023-12-05 | アデノ随伴ウイルス変異キャプシドおよび血管新生の阻害のための使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11766489B2 (enExample) |
| EP (3) | EP3717636B1 (enExample) |
| JP (3) | JP7184894B2 (enExample) |
| KR (2) | KR102793696B1 (enExample) |
| CN (1) | CN111770999A (enExample) |
| AU (3) | AU2018372235B9 (enExample) |
| BR (1) | BR112020010674A2 (enExample) |
| CA (1) | CA3083472A1 (enExample) |
| CL (1) | CL2020001360A1 (enExample) |
| CR (1) | CR20200282A (enExample) |
| DK (1) | DK3717636T5 (enExample) |
| ES (1) | ES2946747T3 (enExample) |
| FI (1) | FI3717636T3 (enExample) |
| IL (1) | IL274712A (enExample) |
| MX (1) | MX2020005451A (enExample) |
| PE (1) | PE20210915A1 (enExample) |
| PH (1) | PH12020550706A1 (enExample) |
| PT (1) | PT3717636T (enExample) |
| SG (1) | SG11202004545XA (enExample) |
| UA (1) | UA127831C2 (enExample) |
| WO (1) | WO2019104279A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| MX2020006435A (es) * | 2017-12-19 | 2021-02-09 | Akouos Inc | Administracion de anticuerpos terapeuticos mediada por vector de virus adenoasociado (aav) en el oido interno. |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| BR112020022858A2 (pt) | 2018-05-11 | 2021-02-23 | Massachusetts Eye And Ear Infirmary | tropismo específico hepático de vírus adeno-associado |
| EP3856913A4 (en) | 2018-09-26 | 2022-10-26 | California Institute Of Technology | Adeno-associated virus compositions for targeted gene therapy |
| WO2021050527A1 (en) * | 2019-09-09 | 2021-03-18 | The Regents Of The University Of California | Compositions and methods for making and using multispecific antibodies |
| AU2020347165A1 (en) * | 2019-09-09 | 2022-03-31 | Massachusetts Eye And Ear Infirmary | Methods and compositions for modulating the interaction between adeno-associated virus (AAV) and the AAV receptor (AAVR) for altered bio-distribution of AAV |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| WO2021084133A1 (en) * | 2019-10-31 | 2021-05-06 | Universität Bern | Aav vector variants for ocular gene delivery |
| AU2021313839A1 (en) * | 2020-07-21 | 2023-03-23 | FTGEN Corp | Composition and method for treating eye diseases |
| CR20230228A (es) | 2020-12-01 | 2023-07-18 | Akouos Inc | Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular |
| US20240067678A1 (en) * | 2020-12-16 | 2024-02-29 | Children's Medical Research Institute | Adeno-associated virus capsids and vectors |
| AU2021399882A1 (en) * | 2020-12-16 | 2023-07-06 | Children's Medical Research Institute | Aav capsids and vectors |
| CN113041360A (zh) * | 2021-04-01 | 2021-06-29 | 深圳廷美奥生物技术有限公司 | 一种用于治疗年龄相关性黄斑变性的药物 |
| CA3210368A1 (en) * | 2021-04-09 | 2022-10-13 | Shengjiang Liu | Compositions and methods for ocular transgene expression |
| WO2022223644A2 (en) | 2021-04-20 | 2022-10-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for treating retinal degenerative disorders |
| KR20240004316A (ko) * | 2021-04-27 | 2024-01-11 | 4디 몰레큘러 테라퓨틱스 아이엔씨. | 혈관신생과 관련된 안구 질환의 치료를 위한 조성물 및 방법 |
| AU2022281825A1 (en) * | 2021-05-28 | 2024-01-18 | Shanghai Regenelead Therapies Co., Ltd. | Recombinant adeno-associated virus having variant capsid, and application thereof |
| WO2022256561A1 (en) * | 2021-06-03 | 2022-12-08 | Dyno Therapeutics, Inc. | Capsid variants and methods of using the same |
| CN113481237A (zh) * | 2021-06-29 | 2021-10-08 | 厦门朔望医药科技有限公司 | 一种预防和治疗新生血管眼部疾病的基因药物 |
| WO2023280157A1 (zh) * | 2021-07-05 | 2023-01-12 | 武汉纽福斯生物科技有限公司 | 一种抗vegf抗体体内表达系统的构建和应用 |
| CA3231028A1 (en) * | 2021-09-06 | 2023-03-09 | Shaoran Wang | Treatment of rpe65-associated eye diseases and disorders |
| WO2023060264A1 (en) | 2021-10-08 | 2023-04-13 | Dyno Therapeutics, Inc. | Capsid variants and methods of using the same |
| CN114057840B (zh) * | 2021-10-14 | 2022-09-20 | 和元生物技术（上海）股份有限公司 | 包含变异的aav9衣壳蛋白的重组腺相关病毒颗粒 |
| CN118201947B (zh) * | 2021-10-28 | 2025-03-21 | 上海天泽云泰生物医药有限公司 | 腺相关病毒衣壳 |
| US20250177573A1 (en) * | 2021-11-19 | 2025-06-05 | The University Of Bristol | Materials & Methods for Treatment of Macular Degeneration |
| EP4442698A4 (en) * | 2021-12-28 | 2025-10-15 | Chengdu Origen Biotechnology Co Ltd | MODIFIED AAV CAPSID PROTEIN AND ITS USE |
| CN119256089A (zh) * | 2022-03-11 | 2025-01-03 | 阿维麦克思生物制药公司 | 用于表达治疗剂的组合物和方法 |
| WO2023236964A1 (zh) * | 2022-06-07 | 2023-12-14 | 成都弘基生物科技有限公司 | 腺相关病毒药物组合物及其用途 |
| CN115850392A (zh) * | 2022-09-28 | 2023-03-28 | 苏州吉恒基因科技有限公司 | 衣壳蛋白融合细胞穿膜肽的腺相关病毒突变体及其应用 |
| WO2024084075A1 (en) | 2022-10-20 | 2024-04-25 | Sparingvision | Compositions and methods for treating retinal degenerative disorders |
| WO2024102703A2 (en) * | 2022-11-07 | 2024-05-16 | The Regents Of The University Of California | Zikv-based gene delivery system |
| CN116621935B (zh) * | 2022-12-08 | 2024-01-26 | 广州派真生物技术有限公司 | 腺相关病毒突变体及其应用 |
| CN115947796A (zh) * | 2022-12-30 | 2023-04-11 | 衠奥生物技术(武汉)有限公司 | 一种重组腺相关病毒载体及其在基因递送中的应用 |
| AU2024254882A1 (en) * | 2023-03-30 | 2025-10-16 | Pharma Cinq, Llc | VECTOR ENCODING ROD-DERIVED CONE VIABILITY FACTOR AND HUMAN IgK SIGNAL SEQUENCE |
| WO2024240113A1 (zh) * | 2023-05-23 | 2024-11-28 | 北京因诺惟康医药科技有限公司 | 一种腺相关病毒衣壳蛋白、包含其的腺相关病毒、载体及应用 |
| CN117247434B (zh) * | 2023-11-10 | 2024-02-02 | 上海朗昇生物科技有限公司 | 衣壳修饰型病毒载体及其制备和用途 |
| CN120005036A (zh) * | 2023-11-14 | 2025-05-16 | 上海朗昇生物科技有限公司 | 用于老年相关性黄斑变性的治疗的基因治疗药物 |
| WO2025103468A1 (zh) * | 2023-11-15 | 2025-05-22 | 成都弘基生物科技有限公司 | 一种重组腺相关病毒药物组合物及其用途 |
| CN117925664B (zh) * | 2023-11-29 | 2025-01-21 | 上海科锐克医药科技有限公司 | 用于递送人vegf受体融合蛋白的基因递送载体及其应用 |
| CN120230798A (zh) * | 2023-12-29 | 2025-07-01 | 上海朗昇生物科技有限公司 | 用于视网膜基因递送的重组腺相关病毒载体及其应用 |
| CN118903383B (zh) * | 2024-10-09 | 2025-02-25 | 中山大学中山眼科中心 | Vegf-b蛋白、vegf-b蛋白活性肽段在制备预防和/或治疗急性前葡萄膜炎的药物中的应用 |
| US12480098B1 (en) | 2024-10-18 | 2025-11-25 | Aavatar Therapeutics Co., Ltd. | Adeno-associated virus variant |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US608200A (en) | 1898-08-02 | Toy cannon | ||
| AU4645697A (en) | 1996-09-11 | 1998-04-02 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Aav4 vector and uses thereof |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| US7323179B2 (en) | 1997-12-19 | 2008-01-29 | Naomi Balaban | Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6984517B1 (en) | 1998-05-28 | 2006-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | AAV5 vector and uses thereof |
| WO1999061601A2 (en) | 1998-05-28 | 1999-12-02 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Aav5 vector and uses thereof |
| DK1127150T3 (da) | 1998-11-05 | 2007-09-24 | Univ Pennsylvania | Nucleinsyresekvenser fra det adeno-associerede virus af serotype 1 samt vektorer og værtsceller, der indeholder disse |
| US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
| DE69941905D1 (de) | 1998-11-10 | 2010-02-25 | Univ North Carolina | Virusvektoren und verfahren für ihre herstellung und verabreichung. |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| CA2376379C (en) | 1999-06-08 | 2007-08-07 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| WO2001029058A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| KR20080023768A (ko) | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체 |
| WO2001089304A1 (en) | 2000-05-23 | 2001-11-29 | University Of Rochester | Method of producing herpes simplex virus amplicons, resulting amplicons, and their use |
| JP4901051B2 (ja) | 2000-05-30 | 2012-03-21 | ジョンソン アンド ジョンソン リサーチ プロプライアトリー リミテッド | ＲＮＡｉを増強する因子を使用することによって遺伝子抑制を媒介する方法 |
| AU2001284160A1 (en) | 2000-08-19 | 2002-03-04 | Axordia Limited | Modulation of stem cell differentiation |
| WO2002029858A2 (en) | 2000-09-29 | 2002-04-11 | Infineon Technologies North America Corp. | Deep trench etching method to reduce/eliminate formation of black silicon |
| EP1356052B1 (en) | 2000-12-14 | 2008-08-20 | Genentech, Inc. | Production of full antibodies in procaryotic cells |
| US7749492B2 (en) | 2001-01-05 | 2010-07-06 | Nationwide Children's Hospital, Inc. | AAV vectors and methods |
| US6962815B2 (en) | 2001-01-05 | 2005-11-08 | Children's Hopital Inc. | AAV2 vectors and methods |
| EP1572893B1 (en) | 2001-11-09 | 2009-01-07 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES | Production of adeno-associated virus in insect cells |
| SG168422A1 (en) | 2001-11-13 | 2011-02-28 | Univ Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
| JP4810062B2 (ja) | 2001-12-17 | 2011-11-09 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | アデノ随伴ウイルス（ａａｖ）血清型８の配列 |
| ES2526341T3 (es) | 2001-12-17 | 2015-01-09 | The Trustees Of The University Of Pennsylvania | Secuencias de serotipo 9 de virus adeno-asociado (AAV), vectores que las contienen, y usos de las mismas |
| US20050106558A1 (en) | 2001-12-21 | 2005-05-19 | Luca Perabo | Library of modified structural genes or capsid modified particles useful for the identification of viral clones with desired cell tropism |
| US20040002159A1 (en) | 2002-04-05 | 2004-01-01 | Weidong Xiao | Methods for the production of chimeric adeno-associated virus (AAV) vectors, compositions of chimeric AAV vectors, and methods of use thereof |
| WO2003089612A2 (en) | 2002-04-17 | 2003-10-30 | University Of Florida Research Foundation, Inc. | IMPROVED rAAV VECTORS |
| AU2003295312B2 (en) | 2002-05-01 | 2008-08-14 | University Of Florida Research Foundation, Inc. | Improved rAAV expression systems for genetic modification of specific capsid proteins |
| US20040023390A1 (en) | 2002-08-05 | 2004-02-05 | Davidson Beverly L. | SiRNA-mediated gene silencing with viral vectors |
| US7220577B2 (en) | 2002-08-28 | 2007-05-22 | University Of Florida Research Foundation, Inc. | Modified AAV |
| US7186522B2 (en) | 2003-03-31 | 2007-03-06 | Cytyc Corporation | Papanicolau staining process |
| WO2004106360A2 (en) | 2003-05-23 | 2004-12-09 | Mount Sinai School Of Medicine Of New York University | Viral vectors with improved properties |
| EP1486567A1 (en) | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
| US8071028B2 (en) | 2003-06-12 | 2011-12-06 | Abbott Diabetes Care Inc. | Method and apparatus for providing power management in data communication systems |
| PL2357189T3 (pl) | 2003-06-19 | 2017-08-31 | Genzyme Corporation | Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie |
| US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| US9233131B2 (en) | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| EP3910063A1 (en) | 2003-09-30 | 2021-11-17 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| EP1791858B1 (en) | 2004-09-24 | 2010-04-21 | Intercell AG | Modified vp1-capsid protein of parvovirus b19 |
| CN101124328A (zh) | 2004-12-15 | 2008-02-13 | 北卡罗来纳查佩尔山大学 | 嵌合载体 |
| EP3409296A1 (en) | 2005-04-07 | 2018-12-05 | The Trustees of the University of Pennsylvania | Method of increasing the function of an aav vector |
| WO2006119432A2 (en) | 2005-04-29 | 2006-11-09 | The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services | Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes |
| PL1945779T3 (pl) | 2005-10-20 | 2013-08-30 | Uniqure Ip Bv | Ulepszone wektory AAV produkowane w komórkach owadzich |
| WO2007089632A2 (en) | 2006-01-27 | 2007-08-09 | The University Of North Carolina At Chapel Hill | Heparin and heparan sulfate binding chimeric vectors |
| EP2007795B1 (en) | 2006-03-30 | 2016-11-16 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid proteins |
| CN101495624A (zh) | 2006-04-28 | 2009-07-29 | 宾夕法尼亚州立大学托管会 | 衣壳免疫原性降低的经修饰aav载体及其用途 |
| US20070274985A1 (en) * | 2006-05-26 | 2007-11-29 | Stefan Dubel | Antibody |
| EP3492596A1 (en) | 2007-04-09 | 2019-06-05 | University of Florida Research Foundation, Inc. | Raav vector compositions having tyrosine-modified capsid proteins and methods for use |
| WO2008124015A1 (en) | 2007-04-09 | 2008-10-16 | The Regents Of The University Of California | Methods for purifying adeno-associated virus virions |
| ES2602610T3 (es) | 2007-05-31 | 2017-02-21 | Medigene Ag | Proteína estructural mutada de un parvovirus |
| EP2012122A1 (en) | 2007-07-06 | 2009-01-07 | Medigene AG | Mutated parvovirus structural proteins as vaccines |
| EP2176283B1 (en) | 2007-07-14 | 2016-11-02 | University of Iowa Research Foundation | Methods and compositions for treating brain diseases |
| WO2009108274A2 (en) | 2008-02-26 | 2009-09-03 | The University Of North Carolina At Chapel Hill | Methods and compositions for adeno-associated virus (aav) with hi loop mutations |
| US8632764B2 (en) | 2008-04-30 | 2014-01-21 | University Of North Carolina At Chapel Hill | Directed evolution and in vivo panning of virus vectors |
| US20110171262A1 (en) | 2008-06-17 | 2011-07-14 | Andrew Christian Bakker | Parvoviral capsid with incorporated gly-ala repeat region |
| JP2010002479A (ja) | 2008-06-18 | 2010-01-07 | Crossfor:Kk | メガネレンズ用装飾体およびメガネ用装飾体装着具 |
| KR102095257B1 (ko) * | 2008-06-25 | 2020-04-01 | 노바르티스 아게 | Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체 |
| US20110275529A1 (en) | 2008-09-19 | 2011-11-10 | Charite Universitatsmedizin Berlin | Identification and characterisation of recombinant viral gene therapy vectors |
| WO2010093784A2 (en) | 2009-02-11 | 2010-08-19 | The University Of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| WO2010141706A1 (en) | 2009-06-03 | 2010-12-09 | Cedars-Sinai Medical Center | Effective vector platform for gene transfer and gene therapy |
| WO2011038187A1 (en) | 2009-09-25 | 2011-03-31 | The Trustees Of The University Of Pennsylvania | Controlled adeno-associated virus (aav) diversification and libraries prepared therefrom |
| US8299295B2 (en) | 2009-10-15 | 2012-10-30 | Johnson Matthey Public Limited Company | Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs |
| US8263396B2 (en) | 2010-04-01 | 2012-09-11 | Weidong Xiao | Methods and compositions for the production of recombinant virus vectors |
| EP3540055A1 (en) | 2010-04-23 | 2019-09-18 | University of Massachusetts | Cns targeting aav vectors and methods of use thereof |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
| CN103025344B (zh) | 2010-05-17 | 2016-06-29 | 桑格摩生物科学股份有限公司 | 新型dna-结合蛋白及其用途 |
| US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| US10415056B2 (en) | 2010-11-10 | 2019-09-17 | Fred Hutchinson Cancer Research Center | Compositions and methods for generating adeno-associated viral vectors with undetectable capsid gene contamination |
| JP6042825B2 (ja) | 2011-02-10 | 2016-12-14 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 改変された形質導入プロファイルを有するウイルスベクターならびにその製造および使用の方法 |
| US10392632B2 (en) | 2011-02-14 | 2019-08-27 | The Children's Hospital Of Philadelphia | AAV8 vector with enhanced functional activity and methods of use thereof |
| SG10202007803QA (en) | 2011-02-17 | 2020-09-29 | Univ Pennsylvania | Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer |
| LT3254703T (lt) | 2011-04-22 | 2020-05-25 | The Regents Of The University Of California | Adenoasocijuoto viruso virionai su variantine kapside ir jų panaudojimo būdai |
| WO2012169822A2 (ko) * | 2011-06-10 | 2012-12-13 | 강원대학교산학협력단 | 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물 |
| KR101397088B1 (ko) | 2011-06-10 | 2014-05-19 | 강원대학교산학협력단 | 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물 |
| ES2857734T3 (es) | 2011-08-23 | 2021-09-29 | Roche Glycart Ag | Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas |
| EP2748185A1 (en) | 2011-08-24 | 2014-07-02 | The Board of Trustees of The Leland Stanford Junior University | New aav capsid proteins for nucleic acid transfer |
| WO2013057235A1 (en) | 2011-10-21 | 2013-04-25 | Intervet International B.V. | Recombinant nonpathogenic mdv vector providing multivalent immunity |
| WO2013096955A1 (en) | 2011-12-23 | 2013-06-27 | Case Western Reserve University | Targeted gene modification using hybrid recombinant adeno-associated virus |
| CN104520428B (zh) | 2012-02-17 | 2018-09-21 | 费城儿童医院 | 将基因转移到细胞、器官和组织的aav载体组合物和方法 |
| CA2870736C (en) | 2012-04-18 | 2021-11-02 | The Children's Hospital Of Philadelphia | Composition and methods for highly efficient gene transfer using aav capsid variants |
| US20140162319A2 (en) | 2012-05-02 | 2014-06-12 | Sangeetha Hareendran | Nucleotide sequences, methods, kit and a recombinant cell thereof |
| JP6385920B2 (ja) | 2012-05-09 | 2018-09-05 | オレゴン ヘルス アンド サイエンス ユニバーシティー | アデノ随伴ウイルスプラスミド及びベクター |
| WO2013174760A1 (en) | 2012-05-25 | 2013-11-28 | Deutsches Krebsforschungszentrum | Optimized aav-vectors for high transduction rates in dendritic cells |
| EP2692731A1 (en) | 2012-07-31 | 2014-02-05 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Recombinant Adeno-Associated virus (AAV) vector particles displaying high-affinity ligands for cell-type specific gene delivery |
| EP3738974A1 (en) | 2012-09-28 | 2020-11-18 | The University of North Carolina at Chapel Hill | Aav vectors targeted to oligodendrocytes |
| JP6363958B2 (ja) | 2012-12-25 | 2018-07-25 | タカラバイオ株式会社 | Ａａｖ変異体 |
| DK2954051T3 (da) | 2013-02-08 | 2019-07-08 | Univ Pennsylvania | Modificeret kapsid til genoverførsel til behandling af nethinden |
| CA2905952A1 (en) | 2013-03-13 | 2014-10-02 | The Children's Hospital Of Philadelphia | Adeno-associated virus vectors and methods of use thereof |
| WO2014194132A1 (en) | 2013-05-31 | 2014-12-04 | The Regents Of The University Of California | Adeno-associated virus variants and methods of use thereof |
| IL294463A (en) * | 2013-07-12 | 2022-09-01 | Iveric Bio Inc | Methods for treating or preventing eye conditions |
| WO2017180936A1 (en) * | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| US11596699B2 (en) | 2016-04-29 | 2023-03-07 | CureVac SE | RNA encoding an antibody |
| MX2018013463A (es) | 2016-05-13 | 2019-07-04 | 4D Molecular Therapeutics Inc | Capsides variantes de virus adenoasociados y metodos de uso de las mismas. |
| PT3795181T (pt) | 2016-06-16 | 2025-11-05 | Adverum Biotechnologies Inc | Tratamento de dmi com utilização da variante aav2 com aflibercept |
| KR102616820B1 (ko) * | 2017-03-17 | 2023-12-21 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | 향상된 유전자 발현을 위한 조성물 및 방법 |
| DK3684423T5 (da) | 2017-09-20 | 2024-08-26 | 4D Molecular Therapeutics Inc | Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf |
| EP3697449A1 (en) * | 2017-10-18 | 2020-08-26 | REGENXBIO Inc. | Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap |
-
2018
- 2018-11-26 JP JP2020528888A patent/JP7184894B2/ja active Active
- 2018-11-26 ES ES18881166T patent/ES2946747T3/es active Active
- 2018-11-26 MX MX2020005451A patent/MX2020005451A/es unknown
- 2018-11-26 SG SG11202004545XA patent/SG11202004545XA/en unknown
- 2018-11-26 CN CN201880087687.3A patent/CN111770999A/zh active Pending
- 2018-11-26 PE PE2020000575A patent/PE20210915A1/es unknown
- 2018-11-26 FI FIEP18881166.5T patent/FI3717636T3/fi active
- 2018-11-26 KR KR1020207017143A patent/KR102793696B1/ko active Active
- 2018-11-26 EP EP18881166.5A patent/EP3717636B1/en active Active
- 2018-11-26 PT PT188811665T patent/PT3717636T/pt unknown
- 2018-11-26 UA UAA202003841A patent/UA127831C2/uk unknown
- 2018-11-26 BR BR112020010674-7A patent/BR112020010674A2/pt unknown
- 2018-11-26 EP EP23186524.7A patent/EP4272728A3/en not_active Withdrawn
- 2018-11-26 CR CR20200282A patent/CR20200282A/es unknown
- 2018-11-26 EP EP23152950.4A patent/EP4219695A3/en active Pending
- 2018-11-26 AU AU2018372235A patent/AU2018372235B9/en active Active
- 2018-11-26 WO PCT/US2018/062478 patent/WO2019104279A1/en not_active Ceased
- 2018-11-26 KR KR1020257011121A patent/KR20250052478A/ko active Pending
- 2018-11-26 DK DK18881166.5T patent/DK3717636T5/da active
- 2018-11-26 CA CA3083472A patent/CA3083472A1/en active Pending
- 2018-11-26 US US16/765,758 patent/US11766489B2/en active Active
-
2020
- 2020-05-17 IL IL274712A patent/IL274712A/en unknown
- 2020-05-22 CL CL2020001360A patent/CL2020001360A1/es unknown
- 2020-05-26 PH PH12020550706A patent/PH12020550706A1/en unknown
-
2022
- 2022-05-23 AU AU2022203494A patent/AU2022203494B2/en active Active
- 2022-06-24 JP JP2022101767A patent/JP2022121534A/ja active Pending
-
2023
- 2023-12-05 JP JP2023205214A patent/JP2024015194A/ja active Pending
-
2024
- 2024-09-24 AU AU2024220028A patent/AU2024220028A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021503914A5 (enExample) | ||
| JP7492556B2 (ja) | 滲出型加齢性黄斑変性の治療のための組成物 | |
| FI3717636T3 (fi) | Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä | |
| CA2873628C (en) | Treatment of amd using aav sflt-1 | |
| ES2916344T3 (es) | Composiciones y métodos para reducir la neovascularización ocular | |
| JP2021097675A (ja) | 中枢神経系を標的化したａａｖベクター | |
| RU2018142768A (ru) | Варианты капсидов аденоассоциированного вируса и способы их применения | |
| AU2021225178A1 (en) | Treatment of AMD using AAV2 variant with aflibercept | |
| JP2024016207A (ja) | 滲出型加齢性黄斑変性の治療のための組成物 | |
| JP2020028308A5 (enExample) | ||
| JP2015523060A5 (enExample) | ||
| TW202532428A (zh) | 用於玻璃體內遞送之變異體aav蛋白殼 | |
| JP7597380B2 (ja) | 対側眼へのａａｖ遺伝子治療の逐次的硝子体内投与 | |
| EP4549459A1 (en) | Aav drug for treating angiogenesis-related fundus diseases | |
| CN117467025B (zh) | 一种抗vegf和补体双功能融合蛋白及其应用 | |
| US20150182638A1 (en) | Virus-mediated delivery of bevacizumab for therapeutic applications | |
| IL300864A (en) | Adeno-associated virus for the administration of KH902 (Conversept) and its uses | |
| CA3080467A1 (en) | Composition comprising raav containing soluble vegfr-1 variant cdna for treatment of macular degeneration | |
| CN119585299A (zh) | 编码抗vegf实体和补体负调节剂的核酸及其用于年龄相关性黄斑变性的治疗的用途 | |
| CN114126667A (zh) | 使用糖苷水解酶的基因疗法载体向视网膜细胞的改进递送 | |
| JPWO2021041373A5 (enExample) | ||
| RU2846105C1 (ru) | Аденоассоциированный вирус для доставки kh902 (конберцепта) и его применения | |
| NZ765038B2 (en) | Adeno-associated virus variant capsids and use for inhibiting angiogenesis | |
| RU2023130643A (ru) | Композиции и способы для лечения заболевания глаз, ассоциированного с ангиогенезом | |
| WO2025103416A1 (zh) | 用于老年相关性黄斑变性的治疗的基因治疗药物 |